来凯(2105.HK)将在2025美国糖尿病协会年会上展示多项ActRII领域自主研发成果

格隆汇资讯
May 27, 2025

2025年5月27日——来凯医药(2105.HK)今日宣布,公司将在美国糖尿病协会(American Diabetes Association, ADA)第85届科学年会上,以壁报形式展示多项增肌减脂领域的研发成果——靶向ActRII的三款单克隆抗体LAE102、LAE103和LAE123的临床前数据,以及其中一款针对ActRIIA的单抗LAE102的首次人体研究数据。ADA科学年会是全球糖尿病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10